Symbols

INO

Inovio Pharmaceuticals·NASDAQ

--(--)

INO fundamentals

INO Q4 2025 Earnings

Inovio Pharmaceuticals (INO) released its earnings on Mar 12, 2026: revenue was 0 (YoY -100.00%), met estimates; EPS was -0.26 (YoY +60.00%), beat estimates.

Revenue / YoY

-100.00%

EPS / YoY

-0.26

+60.00%

Report date

Mar 12, 2026

INO Earnings Call Summary for Q4,2025

FDA Milestone Progress: INO-3107 BLA under accelerated review with PDUFA date October 2026; awaiting FDA meeting to resolve eligibility concerns.
Clinical Efficacy: 72% of patients saw 50%-100% surgery reduction in first year, improving to 86% by year two, with no surgery requirement during treatment.
Financial Sustainability: $58.5M cash on hand, extended runway to Q4 2026, and 23% reduction in annual operational expenses.
Commercial Readiness: Finalizing partnerships and go-to-market strategy for rapid launch, leveraging RRP Foundation's first-line immunotherapy endorsement.
Pipeline Expansion: Exploring partnerships for DPROT and dMAb programs while advancing late-stage candidates like INO-3112 post-approval.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Inovio Pharmaceuticals (INO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Inovio Pharmaceuticals (INO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Inovio Pharmaceuticals (INO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Inovio Pharmaceuticals (INO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown